Biocross is a biotechnology company that seeks to improve
the life expectancy and quality of life of individuals with neurodegenerative diseases
through the design of innovative diagnostic systems.
This is achieved through the development of reliable
and non-invasive diagnostic tools that can be used
at any stage of the disease.
Early diagnosis
Biocross provides diagnostic solutions that can be used during the asymptomatic phase of the disease and enable early detection of individuals with increased risk of developing dementia.
Reliable
Biocross has designed its products with a commitment to providing diagnostic tests of higher sensitivity and specificity than any currently available systems.
Non-invasive
All of our diagnostic tests are based on the analysis of blood samples, and are applicable in hospital settings, thus ensuring patient safety and comfort.
Our goal
To provide neurologists with an integrated diagnostic solution that can be applied to any stage of the disease, including the earliest, asymptomatic phase.
Benefits
- Reduced cost of AD risk-assessment and diagnosis.
- More widespread testing thanks to simpler, more readily available diagnostic methods.
- Improved diagnosis, through earlier detection and differentiation of distinct dementia types.
- Simplified diagnosis through leveraging of existing laboratory equipment.
- Improved patient experience and safety.
Our products
The ApoE4 blood marker assay is a non-genetic, cost-effective, and highly reliable method to detect the presence of the ApoE4 protein in human blood plasma using high-throughput chemical analysis.
The AD Dementia test is a multiparametric test that combines the detection and quantification of up to 9 metabolites or proteins in a plasma sample. The input of these measurements into an algorithm provides an accurate diagnosis and classifies the patient as either Alzheimer´s disease or frontotemporal dementia.
The Degenerative dementia test is based on the detection and quantification of up to 7 blood biomarkers that are specifically altered in patients affected by neurodegeneration due to FTD or AD. The DD test is conceived as a “screening” tool for use in clinical practice.
Biocross´ news
Entrevista con Matt Mittino, CEO de Biocross
“Tenemos una prueba que determina el riesgo de desarrollar la enfermedad de Alzheimer en 10 minutos” Escrito por Silvia Martin el 3 noviembre, 2017 en Reportajes En esta entrevista, el máximo responsable de Biocross, Matt Mittino, explica que uno de sus objetivos es...
read more
Diez minutos y una consulta rutinaria bastarán para detectar el Alzheimer
Diez minutos es el tiempo que tarda la cafeína en hacer efecto tras beber un café y poco más que los ocho que tarda la luz del sol en llegar a nuestro planeta, pero además es el lapso que tardará una prueba médica desarrollada por Biocross en identificar factores de...
read more
La prevención y la detección precoz del Alzheimer, el gran reto de los expertos en la materia
Con motivo del Día Mundial del Alzheimer, que se celebra el 21 de septiembre, en entremayores repasamos algunas de las iniciativas en pro de la prevención y la detección precoz de esta dolencia que afecta a una de cada diez personas mayores de 65 años. Asimismo,...
read moreIf you have any questions or comments, we will be pleased to attend you
If you have any questions or comments,
we will be pleased to attend you
Avda. Francisco Vallés, 8
47151 Boecillo (Valladolid) - Spain
+34 983 54 98 96